Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

2.

New oral anticoagulants for atrial fibrillation: a review of clinical trials.

O'Dell KM, Igawa D, Hsin J.

Clin Ther. 2012 Apr;34(4):894-901. doi: 10.1016/j.clinthera.2012.01.019. Epub 2012 Mar 13. Review.

PMID:
22417716
3.
4.

Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa.

Bauer KA.

J Thromb Haemost. 2011 Jul;9 Suppl 1:12-9. doi: 10.1111/j.1538-7836.2011.04321.x. Review.

5.

Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors.

Eriksson BI, Dahl OE.

Drugs. 2004;64(6):577-95. Review. Erratum in: Drugs. 2004;64(8):912.

PMID:
15018589
6.

Rivaroxaban: an oral direct inhibitor of factor Xa.

Gulseth MP, Michaud J, Nutescu EA.

Am J Health Syst Pharm. 2008 Aug 15;65(16):1520-9. doi: 10.2146/ajhp070624. Review.

PMID:
18693206
8.

Selection and assessment of patients treated with the novel oral anticoagulant drugs: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.

Ageno W, Crowther M, Baglin T, Falanga A, Buller H, Palareti G; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.

J Thromb Haemost. 2013 Jan;11(1):177-9. doi: 10.1111/jth.12038. No abstract available.

9.

[Pharmacology of the new oral anticoagulants].

Dempfle CE.

Herz. 2012 Jun;37(4):362-8. doi: 10.1007/s00059-012-3616-y. German.

PMID:
22565859
10.

Novel anticoagulant therapy: principle and practice.

Mousa SA.

Methods Mol Biol. 2010;663:157-79. doi: 10.1007/978-1-60761-803-4_5. Review.

PMID:
20617417
11.

Novel antithrombotic agents: indirect synthetic inhibitors of factor Xa and direct thrombin inhibitors. Evidences from clinical studies.

Leone G, Rossi E, Leone AM, De Stefano V.

Curr Med Chem Cardiovasc Hematol Agents. 2004 Oct;2(4):311-26. Review.

PMID:
15320782
12.

The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants.

Samama MM.

Thromb Res. 2011 Jun;127(6):497-504. doi: 10.1016/j.thromres.2010.09.008. Epub 2010 Oct 2. Review.

PMID:
20888031
13.

Clinical trials of direct thrombin and factor Xa inhibitors in atrial fibrillation.

Stewart RA.

Curr Opin Cardiol. 2011 Jul;26(4):294-9. doi: 10.1097/HCO.0b013e3283477dbc. Review.

PMID:
21537165
14.

Development and clinical applications of novel oral anticoagulants. Part I. Clinically approved drugs.

Ahrens I, Peter K, Lip GY, Bode C.

Discov Med. 2012 Jun;13(73):433-43. Review.

15.

Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.

Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S; ODIXa-DVT Study Investigators.

Circulation. 2007 Jul 10;116(2):180-7. Epub 2007 Jun 18.

16.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
17.

Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome.

Noel N, Dutasta F, Costedoat-Chalumeau N, Bienvenu B, Mariette X, Geffray L, Sene D, Chaidi RB, Michot JM, Fain O, Darnige L, Ankri A, Cacoub P, Piette JC, Saadoun D.

Autoimmun Rev. 2015 Aug;14(8):680-5. doi: 10.1016/j.autrev.2015.03.007. Epub 2015 Apr 9. Review.

PMID:
25864630
18.

New anticoagulants: anti IIa vs anti Xa--is one better?

Bauer KA.

J Thromb Thrombolysis. 2006 Feb;21(1):67-72. Review.

PMID:
16475045
19.

Oral anticoagulation with factor Xa and thrombin inhibitors: on the threshold of change.

Zikria JC, Ansell J.

Curr Opin Hematol. 2009 Sep;16(5):347-56. doi: 10.1097/MOH.0b013e32832ea2d7.

PMID:
19550318
20.

Update on pharmacologic approaches to prevent thromboembolism in atrial fibrillation: are thrombin and factor Xa inhibitors the ultimate answer?

Wolfram O, Hammwoehner M, Gramley F, Goette A.

Curr Vasc Pharmacol. 2011 May;9(3):350-7. Review.

PMID:
21143166

Supplemental Content

Support Center